pharma · Renal Transplantation · Rheumatoid Arthritis (RA)
Astellas Pharma
Astellas Pharma Inc
Astellas Pharma is a pharma organization headquartered in CN. Primary therapeutic focus areas include Renal Transplantation, Rheumatoid Arthritis (RA), Non-small Cell Lung Cancer, Restless Legs Syndrome, Hot Flashes. Nov
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 20
- Drugs
- 12
- Patents
- 25
Quick answer
Astellas Pharma is a pharma organization headquartered in CN. Primary therapeutic focus areas include Renal Transplantation, Rheumatoid Arthritis (RA), Non-small Cell Lung Cancer, Restless Legs Syndrome, Hot Flashes. NovaPharmaNews links 20 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (10), phase 2 (5), phase 1 (3).
Company snapshot
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas Li
- 4 approved product(s) across US/EU regulatory metadata.
- 20 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Astellas Pharma. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- deal
Fierce Pharma Asia: Key Insights on Recent Deals and Trends
- approval
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
Recent coverage
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
Fierce Pharma Asia: Key Insights on Recent Deals and Trends
This article provides a comprehensive overview of the latest developments in the pharmaceutical industry, focusing on Pfizer's $10B Innovent deal and Astellas' strategic roadmap.
Astellas Cuts Costs Amid FDA Review of Moderna Vaccine
Astellas Pharma is implementing cost reductions as the FDA panel prepares to review the Moderna vaccine. This article explores the implications for the pharmaceutical industry.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Astellas Pharma.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Astellas Pharma.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Astellas Pharma?
-
Is Astellas Pharma publicly traded?
-
What drugs does Astellas Pharma develop or market?
-
What are the latest developments for Astellas Pharma?
-
What therapeutic areas does Astellas Pharma focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.